<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004664</url>
  </required_header>
  <id_info>
    <org_study_id>199/11931</org_study_id>
    <secondary_id>NU-516</secondary_id>
    <nct_id>NCT00004664</nct_id>
  </id_info>
  <brief_title>Randomized Placebo-Controlled Study of Aerobic Exercise and Resistance Training Plus Megestrol Acetate for HIV-Wasting</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Office of Rare Diseases (ORD)</source>
  <brief_summary>
    <textblock>
      OBJECTIVES: I. Evaluate the effect of aerobic exercise and progressive resistance plus&#xD;
      megestrol acetate on lean body mass of patients with human immunodeficiency virus-related&#xD;
      weight loss (HIV-wasting).&#xD;
&#xD;
      II. Evaluate whether exercise acutely alters immune function. III. Evaluate whether long-term&#xD;
      exercise improves immunocompetence. IV. Evaluate the accuracy of multifrequency bioelectrical&#xD;
      impedance spectral analysis in measuring body composition.&#xD;
&#xD;
      V. Assess the impact of these therapies on quality of life. VI. Evaluate the effect of these&#xD;
      therapies on the balance of energy intake and energy expenditure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE: Patients are randomly assigned to 1 of 3 therapy groups: megestrol acetate&#xD;
      alone, exercise plus megestrol acetate, or exercise plus placebo. Therapy continues for 12&#xD;
      weeks.&#xD;
&#xD;
      A single dose of oral megestrol acetate or placebo is administered each morning.&#xD;
&#xD;
      The exercise program consists of aerobic exercise and resistance training performed 3 times a&#xD;
      week under supervision. Hard aerobic exercise is performed for 45 minutes plus a warm-up and&#xD;
      cool-down period; the patient chooses to work on 3 of 5 pieces of exercise equipment.&#xD;
      Exercise intensity is adjusted to a heart rate corresponding to 65% of maximal oxygen&#xD;
      consumption.&#xD;
&#xD;
      Resistance training is done on a universal gym; exercises are designed to work all 6 major&#xD;
      muscle groups. Each exercise is performed at 70% of maximal single repetition resistance.&#xD;
      Resistance is increased 5% when the patient can perform 15 repetitions without failure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 1995</start_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>69</enrollment>
  <condition>Acquired Immunodeficiency Syndrome</condition>
  <condition>HIV Wasting Syndrome</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>megestrol</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Exercise</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:&#xD;
&#xD;
        --Disease Characteristics--&#xD;
&#xD;
        Human immunodeficiency virus seropositive with acquired immune deficiency syndrome&#xD;
&#xD;
        Documented weight loss 5% to 15% below ideal weight&#xD;
&#xD;
        --Prior/Concurrent Therapy--&#xD;
&#xD;
        No concurrent appetite stimulants&#xD;
&#xD;
        At least 6 weeks since initiation of new antiretroviral therapy&#xD;
&#xD;
        --Patient Characteristics--&#xD;
&#xD;
        Performance status: Karnofsky 70%-100%&#xD;
&#xD;
        Hepatic: No ascites&#xD;
&#xD;
        Renal: No nephrosis&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No acute or untreated infection within 4 weeks prior to entry&#xD;
&#xD;
          -  No hospitalization within 2 weeks prior to entry&#xD;
&#xD;
          -  No gonadal insufficiency&#xD;
&#xD;
          -  No edema&#xD;
&#xD;
          -  No pleural effusion&#xD;
&#xD;
          -  No uncontrolled diarrhea&#xD;
&#xD;
          -  No physical or functional obstruction to food intake&#xD;
&#xD;
          -  No physical handicap that would prevent resistance or aerobic exercise&#xD;
&#xD;
          -  No cardiac abnormality that would render aerobic exercise a health risk&#xD;
&#xD;
          -  No concurrent regular exercise of 3 or more hours a week&#xD;
&#xD;
          -  No mental incompetence&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jamie Hayden Von Roenn</last_name>
    <role>Study Chair</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <verification_date>December 2001</verification_date>
  <study_first_submitted>February 24, 2000</study_first_submitted>
  <study_first_submitted_qc>February 24, 2000</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2000</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>disease-related problem/condition</keyword>
  <keyword>human immunodeficiency virus infection</keyword>
  <keyword>immunologic disorders and infectious disorders</keyword>
  <keyword>nutrition</keyword>
  <keyword>rare disease</keyword>
  <keyword>viral infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Wasting Syndrome</mesh_term>
    <mesh_term>Wasting Syndrome</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Cachexia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Megestrol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

